促红细胞生成素干预肾性贫血治疗靶目标的临床观察

The clinical observation of erythropoietin to intervene in renal anemia treatment target

目的:探讨给予每周不同剂量的促红细胞生成素干预肾性贫血靶目标所需时间的比较,以及在达到靶目标时间内是否会引起血压升高。方法:将69例肾性贫血患者随机分为3组。A组为每周促红素总剂量6000单位治疗,B组为每周促红素总剂量9000单位治疗,C组为每周促红素总剂量12000单位治疗,均皮下注射,治疗8周。观察3组治疗前后血红蛋白(HGB)、血细胞压积(HCT)、血压(BP)变化。结果:治疗前后3组的血红蛋白、红细胞压积均有非常明显的提高,组内、组间有显著性差异(P<0.05),其中C组达到靶目标时间所用最短,在达到靶目标时间内,组间血压比较无显著性差异(P>0.05)。结论:在治疗达到靶目标时间内,促红素的剂量与所需治疗时间成正比关系且不会引起血压升高。

Objective： To compare the time of given weekly doses ot erythropoletm to intervene m renat anemia treatment targets, and explored whether blood pressure could be increased within the time achieving the target. Methods：69 patients with renal anemia were randomly divided into three groups. Group A was treated with a total dose of 6000 units of erythropoietin a week. Group B was treated with a total dose of 9000 units of erythropoietin a week. Group C was treated with a total dose of 12000 units of erythropoietin a week, all in subcutaneous injection method and 8 weeks treatment. To observe the changes of three groups of HGB, HCT and BP. Results.- HGB, HCT and BP in three groups have been obviously improved before and after treat- ment, and there are significant differences among groups and within the group. The time for Group C to achieve his target is the shortest. Conclusion： Within the treatment period to achieve the target time, the dose of erythropoietin is proportional to the required treatment time, meanwhile, it does not cause blood pressure in- creasing.